Working with ETH Zurich researchers, the firm has incorporated machine learning to improve the platform's performance in complex organisms like humans.
The company is working with German informatics firm MSAID to incorporate deep learning into mass spec analysis and with Biognosys on tools for quantitative work.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
The recent agreement between Freenome and Biognosys suggests a role for proteomics as developers of genomic-based cancer detection tests look beyond ctDNA.
Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
